BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19706814)

  • 21. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA; Di X; Walker TD; Sawyer ST
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.
    Pohl G; Rudas M; Dietze O; Lax S; Markis E; Pirker R; Zielinski CC; Hausmaninger H; Kubista E; Samonigg H; Jakesz R; Filipits M
    J Clin Oncol; 2003 Oct; 21(19):3594-600. PubMed ID: 14512390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
    Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
    Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
    Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer.
    Giltnane JM; Rydén L; Cregger M; Bendahl PO; Jirström K; Rimm DL
    J Clin Oncol; 2007 Jul; 25(21):3007-14. PubMed ID: 17634479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
    Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
    Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of erythropoietin and erythropoietin receptor in tongue squamous cell carcinoma.
    Li HG; Li JS; Chen WL; Wang L; Wu DH; Lin ZY
    Br J Oral Maxillofac Surg; 2009 Sep; 47(6):470-5. PubMed ID: 19559511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
    Murphy LC; Niu Y; Snell L; Watson P
    Clin Cancer Res; 2004 Sep; 10(17):5902-6. PubMed ID: 15355923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
    Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low SAFB levels are associated with worse outcome in breast cancer patients.
    Hammerich-Hille S; Bardout VJ; Hilsenbeck SG; Osborne CK; Oesterreich S
    Breast Cancer Res Treat; 2010 Jun; 121(2):503-9. PubMed ID: 19137425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
    Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment.
    Xie Z; Wu X; Qiu Q; Gong Y; Song Y; Gu Q; Li C
    Curr Eye Res; 2007 Sep; 32(9):757-64. PubMed ID: 17882708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.